Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.
Saved in:
| Title: | Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells. |
|---|---|
| Authors: | Pizzarella D; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Kofides A; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Hatcher JM; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Liu X; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Guijosa A; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Tsakmaklis N; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Peachey AL; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Guerrera ML; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Patterson CJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Hunter ZR; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Sun H; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Sarosiek SR; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Buhrlage SJ; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Dhe-Paganon S; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Branagan AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Treon SP; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Liu S; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. |
| Source: | Blood advances [Blood Adv] 2026 Jul 14; Vol. 10 (13), pp. 4450-4454. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
